Alder BioPharmaceuticals (NASDAQ: ALDR) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Alder BioPharmaceuticals to similar companies based on the strength of its dividends, institutional ownership, earnings, analyst recommendations, profitability, valuation and risk.
This table compares Alder BioPharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Alder BioPharmaceuticals Competitors||-5,355.33%||-433.53%||-38.99%|
Alder BioPharmaceuticals has a beta of 2.48, meaning that its stock price is 148% more volatile than the S&P 500. Comparatively, Alder BioPharmaceuticals’ peers have a beta of 1.83, meaning that their average stock price is 83% more volatile than the S&P 500.
This is a breakdown of current ratings for Alder BioPharmaceuticals and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Alder BioPharmaceuticals Competitors||845||3193||11581||230||2.71|
Alder BioPharmaceuticals presently has a consensus price target of $30.58, suggesting a potential upside of 191.27%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.11%. Given Alder BioPharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Alder BioPharmaceuticals is more favorable than its peers.
Valuation & Earnings
This table compares Alder BioPharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Alder BioPharmaceuticals||$110,000.00||-$156.25 million||-1.96|
|Alder BioPharmaceuticals Competitors||$284.30 million||$34.29 million||129.23|
Alder BioPharmaceuticals’ peers have higher revenue and earnings than Alder BioPharmaceuticals. Alder BioPharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
96.9% of Alder BioPharmaceuticals shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 10.6% of Alder BioPharmaceuticals shares are held by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Alder BioPharmaceuticals beats its peers on 7 of the 12 factors compared.
Alder BioPharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder’s third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.
What are top analysts saying about Alder BioPharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alder BioPharmaceuticals Inc. and related companies.